TITLE

CLINIC ROUNDUP

PUB. DATE
September 2009
SOURCE
BioWorld Today;9/17/2009, Vol. 20 Issue 179, p9
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to pharmaceutical industry. Israel-based Can-Fite BioPharma completed its Phase II study on CF101 drug designed to cure psoriasis. The Seattle, Washington-based Cell Therapeutics Inc. accomplished its purpose in the Phase III study called EXTEND aimed at treating non-Hodgkin's lymphoma with advanced condition. A positive outcome was achieved by Addison, Texas-based Uluru Inc. from its research on the treatment of skin graft donor using the wound dressing product Altrazeal.
ACCESSION #
44324387

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;8/2/2011, Vol. 22 Issue 148, p7 

    The article reports on the enrollment in a Phase II/III trial of CF101, a drug for psoriasis, developed by Can-Fite BioPharma Ltd.

  • Dermatology.  // CenterWatch Weekly;4/6/2015, Vol. 19 Issue 13, p9 

    This article discusses the results of a phase II/III trial by pharmaceutical company Can-Fite BioPharma on the efficacy of the drug CF101 in patients with moderate-to-severe plaque psoriasis.

  • CLINIC ROUNDUP.  // BioWorld Today;5/6/2008, Vol. 19 Issue 88, p4 

    This section offers news briefs on the pharmaceutical industry. Anesiva Inc. has announced the publication of data from a Phase III trial of Zingo powder intradermal injection in "Journal Pediatrics." Can-Fite BioPharma has successfully completed a Phase I trial with its second pipeline drug,...

  • Can-Fite: therapeutic approach bolstered by positive results in psoriasis trial.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p18 

    The article reports on the positive outcome of the psoriasis trial of Israel-based biopharmaceutical firm Can-Fite Biopharma Ltd. The 75-patient Phase II double-blind clinical study of the anti-TNF drug CF101 in patients with moderate to severe psoriasis resulted to efficacy upon oral...

  • Pharmaceutical Company Round-Up.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p3 

    The article offers news briefs related to pharmaceutical industry. Dainippon Sumitomo Pharma Co. Ltd. has made an agreement to acquire Sepracor Inc. for approximately 2.6 billion dollars. The advisory committee of the Food & Drug Administration (FDA) has voted against the approval of including...

  • OTHER NEWS TO NOTE.  // BioWorld Today;1/21/2010, Vol. 21 Issue 13, p2 

    This section offers news briefs about the pharmaceutical industry as of January 21, 2010. Can-Fite BioPharma Ltd. signed a deal with Morningside Asia Venture Ltd. for a joint venture which will provide an exclusive license to intellectual property relating to CF102. The Victoza of Novo Nordisk...

  • Other News To Note.  // BioWorld Today;10/24/2013, Vol. 24 Issue 205, p2 

    This section offers news briefs on the biopharmaceutical industry. The U.S. Food and Drug Administration (FDA) has moved to December 12, 2013 a meeting to discuss the biologics license application for the investigational grass allergy immunotherapy (ATI) tablets by drug makers Alk-Abello A/S and...

  • Cell Therapeutics: pixantrone to be submitted for FDA approval in NHL.  // PharmaWatch: Monthly Review;Mar2009, Vol. 8 Issue 3, p7 

    The article reports on the plan of Cell Therapeutics Inc. to secure approval of pixantrone in relapsed aggressive non-Hodgkin's lymphoma (NHL) from the U.S. Food & Drug Administration (FDA) before the end of 2009. Pixantrone was believed to have high chances of approval after results from the...

  • Cell Therapeutics: named EU patients to receive pixantrone for NHL.  // PharmaWatch: Monthly Review;Mar2009, Vol. 8 Issue 3, p8 

    The article reports on the plan of biopharmaceutical firm Cell Therapeutics Inc. to conduct a compassionate use program for pixantrone in patients with relapsed aggressive non-Hodgkin's lymphoma (NHL) in Europe. The program, which was set to start by the second quarter of 2009, was intended to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics